Novartis raised its 2024 earnings guidance for the third time on Tuesday, buoyed by wider use of its prescription drugs, but ...

Novartis has responded ... of the IRA's approach to drug negotiations – said he was surprised at the inclusion of Entresto, as well as some others on the list, including AstraZeneca's Farxiga ...

Novartis NVS announced that the Committee for Medicinal Products for Human Use (“CHMP”) of the European Medicines Agency (EMA ...

For pharma companies, the goldilocks earnings scenario is a strong quarterly beat paired with a promising pipeline of innovative drugs. This balance is crucial for the industry, where firms face the ...

Oct 16 (Reuters) - Novartis (NOVN.S), opens new tab has lost a bid to keep a generic version of its top-selling heart failure drug Entresto off the U.S. market by blocking regulators from ...

Operator Good morning and good afternoon, and welcome to the Novartis Q3 2024 results release conference call and live ...

A new survey shows that three Big Pharmas have stolen the hearts of patient groups representing nearly 1 million people with cardiovascular conditions. | A new survey shows that three Big Pharmas have ...

However, MSN’s product is “consistent ... according to a list of negotiated prices published over the summer. Entresto is Novartis’ bestselling drug: For all of 2023, the heart failure ...

Novartis reported strong third-quarter sales of $12.823 billion, beating consensus, with key growth drivers contributing to momentum and upgraded guidance for 2024.

Swiss pharmaceutical giant Novartis raised its 2024 financial targets Tuesday after posting rising sales and margins in the third quarter, thanks in part to increased production of a prostate cancer ...

Basel, October 18, 2024 – Novartis announced today that the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) has adopted a positive opinion and ...